Tribulus

Tribulus terrestris contains steroidal saponins that inhibit platelet aggregation in vitro (via TXA2 pathway inhibition) and may inhibit vitamin K production by intestinal flora, enhancing the anticoagulant effect of warfarin. Tang (2007) reported that Tribulus preparations can enhance warfarin anticoagulation by interfering with platelet aggregation and affecting warfarin metabolism. The mechanism of CYP2C9 interaction (metabolises S-warfarin) requires further investigation.

Monitor INR closely when Tribulus supplements are started or stopped in patients on warfarin therapy. Advise patients to notify their anticoagulation provider before using Tribulus. Consider INR check within 1-2 weeks of initiating Tribulus supplementation. Discontinue Tribulus at least 2 weeks before elective surgery.

Tribulus terrestris has ACE-inhibitory activity and vasodilatory effects via upregulation of endothelial nitric oxide synthase (eNOS), demonstrated in 2K1C hypertensive rat models (Sharifi AM et al. 2003) and in vitro pharmacological studies. These mechanisms produce additive blood pressure lowering when combined with antihypertensive medications, increasing the risk of symptomatic hypotension.

Monitor blood pressure in patients combining Tribulus with antihypertensive medications, particularly ACE inhibitors or ARBs where the mechanism overlap is most direct. Caution patients about dizziness and orthostatic hypotension. If significant blood pressure drops are noted, consult the prescriber about reviewing antihypertensive doses.

Tribulus terrestris saponins (especially furostanol and spirostanol saponins) demonstrate hypoglycaemic activity in animal studies through insulin-secretion enhancement, peripheral insulin sensitisation, and inhibition of intestinal glucose absorption (Li M et al. 2002). Studies in diabetic rats show significant blood glucose reduction. Additive hypoglycaemic effect with antidiabetic medications increases the risk of hypoglycaemia.

Warn patients with diabetes using Tribulus supplements of the potential for additive hypoglycaemia, especially with insulin or sulfonylureas. Recommend self-monitoring of blood glucose when starting Tribulus. Alert prescribers to Tribulus use so antidiabetic doses can be reviewed if glucose targets are consistently undershot.

Tribulus terrestris is a moderate CYP3A4 inhibitor based on preclinical data. A clinical case report documented rhabdomyolysis in a 71-year-old male on atorvastatin 40 mg/day after starting Tribulus terrestris 500 mg daily, with CK elevation to 7555 U/L, consistent with statin-induced myopathy precipitated by CYP3A4 inhibition reducing statin clearance. Increased statin plasma concentrations from CYP3A4 inhibition can cause severe muscle damage.

Avoid combining Tribulus terrestris with CYP3A4-metabolized statins (atorvastatin, simvastatin, lovastatin). If a patient on statins wishes to use Tribulus, consult the prescriber. Educate patients on symptoms of rhabdomyolysis: severe muscle pain, weakness, dark brown urine (myoglobinuria). If these occur, stop Tribulus and statin immediately and seek urgent medical attention.

A case series reported stent thrombosis in patients taking clopidogrel concurrently with an herbal formula containing Tribulus. Tribulus saponins may compete with or interfere with clopidogrel's active metabolite binding to the P2Y12 ADP receptor on platelets, potentially reducing the antiplatelet efficacy of clopidogrel. This is particularly dangerous in patients with recent coronary stent implantation, where dual antiplatelet therapy failure can cause acute stent thrombosis.

Avoid combining Tribulus terrestris with clopidogrel in patients with coronary artery stents or acute coronary syndrome. Inform cardiologists if any patient on dual antiplatelet therapy (aspirin + clopidogrel) is using Tribulus. Monitor for chest pain or symptoms of acute coronary syndrome. This is potentially a high-risk interaction in cardiac patients.

In vitro studies show that saponins and phenolic compounds from Tribulus terrestris inhibit P-glycoprotein (P-gp/ABCB1) efflux transporter activity. Inhibition of P-gp increases oral bioavailability and reduces renal/biliary clearance of P-gp substrate drugs, potentially elevating their plasma concentrations to toxic levels. Digoxin is particularly vulnerable given its narrow therapeutic index.

Monitor plasma concentrations and clinical response of P-gp substrate drugs in patients using Tribulus supplements. For digoxin, check drug levels and monitor for signs of toxicity (nausea, visual disturbances, bradycardia). For dabigatran, monitor for bleeding. For tacrolimus, monitor trough levels and renal function.